15-03-2023, 03:39

Cullinan Oncology to Present New Preclinical Data for

CLN-619 is a MICA/B directed humanized IgG1 antibody being studied in a global Phase 1 clinical trial in patients with
Globe Newswire15-03-2023, 03:39
14-02-2023, 07:09

Cullinan Oncology Licenses U.S. Rights to the First

CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX:
Globe Newswire14-02-2023, 07:09